LW402 vs VC005

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1 · full Atopic Dermatitis pipeline

LW402

Developed by Shanghai Longwood Biopharmaceuticals

Phase 3 in Atopic Dermatitissmall molecule
Partial signal

NCT07186387 · Phase 2 · completed

The trial was randomized and quadruple-blind, used a placebo control, and enrolled 144 participants; its primary endpoint was a clinical disease-response measure (EASI-50). Because the primary comparison result is not available, the study provides well-designed but incomplete evidence rather than evidence of a confirmed favorable effect.

Next expected readout: March 2028 · NCT07370909 (registry estimate)

No aligned efficacy figure on record for this race.

VC005

Developed by Jiangsu Vcare Pharmatech and partners

Phase 3 in Atopic Dermatitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT07598383 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLW402VC005
EASI-75—Trial running · NCT07370909—Trial running · NCT07592585
IGA 0/1 with 2-point improvement—Trial running · NCT07370909—Trial running · NCT07592585
EASI-90—Trial running · NCT07370909—Trial running · NCT07592585
EASI, % change—Trial running · NCT07370909—Trial running · NCT07592585

EASI-75

LW402
—Trial running · NCT07370909
VC005
—Trial running · NCT07592585

IGA 0/1 with 2-point improvement

LW402
—Trial running · NCT07370909
VC005
—Trial running · NCT07592585

EASI-90

LW402
—Trial running · NCT07370909
VC005
—Trial running · NCT07592585

EASI, % change

LW402
—Trial running · NCT07370909
VC005
—Trial running · NCT07592585
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

LW402: no structured comparison results are available for Atopic Dermatitis.

VC005: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LW402's landscape · VC005's landscape